Point Therapeutics' PT-630 demonstrates long-term benefits in treatment of diabetes

By Lisa Kerner

Charlotte, N.C., June 27 - Point Therapeutics, Inc. said in side-by-side experiments using Zucker Diabetic Fatty rats, a single dose of its diabetes compound PT-630 demonstrates longer term benefits in both elevation of GLP-1 levels and lowering of plasma glucose at later times than a cyanopyrrolidine (CP) DPP-4 inhibitor in animals.

After 44 days of daily dosing, PT-630 was more effective than (CP) DPP-4 inhibitor and metformin in improving whole body sensitivity to insulin and reducing fasting plasma triglycerides, glucose levels and HbA1c.

Point said there no similar reductions in triglycerides and glucose levels with metformin and the CP-inhibitor, and HbA1c was only reduced by 0.9% and 0.5%, respectively, with metformin and the CP-inhibitor.

The company presented its findings in a preclinical poster at the Endocrine Society Annual Meeting.

Point is a Boston-based biopharmaceutical company developing a portfolio of dipeptidyl peptidase inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.